Parkinson's disease progresses to stages where oral treatments become insufficient. While continuous subcutaneous foslevodopa/foscarbidopa (fLD/fCD), a less invasive option, improves motor control, yet little is known about patients and caregivers experiences. This phenomenological study explores these perspectives in Quebec to inform better support, adherence and quality of life.
